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Abstract Systemic lupus erythematosus (SLE) is an autoim-
mune disorder with complex genetic underpinnings. This re-
view attempts to assemble the myriad of genomic findings to
build a clearer picture of the pathobiology of SLE to serve as a
guide for therapeutics. Over 100 genes are now known for
SLE, and several more penetrant ones have led to the emer-
gence of more defined lupus phenotypes. Also discussed here
are the targeted therapies that have come up on the horizon
and the specific biologic mechanisms of more traditional ther-
apies which have only recently been explored. The diagnostic
toolbox has been enhanced by the addition of new antibodies,
gene expression signatures, and mutation panels. This pro-
vides an opportunity to piece together the lupus puzzle and
even revisit the clinical classification of SLE.
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Introduction
Lupus is a syndrome rather than a single disease. Based on the
ACR criteria 1997, there are 330 types of lupus possible [11!/
(4! × 7!)]. This phenotypic variability makes every lupus pa-
tient unique and uniform clinical classification difficult.
Consequently, molecular pathobiology of lupus, which has
the potential for improved clinical disease definition and pro-
viding targeted therapies, becomes challenging. Lupus defini-
tion has evolved over time from exclusively dermatologic to
multiorgan systemic disease (Scofield and Oates 2009). The
discovery of the LE cell and antibodies to DNA in the mid-
twentieth century further transformed lupus diagnosis and sig-
nificantly impacted its clinical management (Hargraves et al.
1948; Deicher et al. 1959). Discovery of immunological fea-
tures such as immune complex deposition in lupus nephritis
(LN), low serum levels of complement components, and a
variety of autoantibodies made lupus a more defined entity
by early 1980s (Koffler et al. 1974; Jennette and Hipp 1985;
Kunkel 1983). Since then, significant advances in the genetics
of systemic lupus erythematosus (SLE) have taken place
which are helping unravel the lupus enigma and will in the
near future even define therapy. Here, we review the pathobi-
ology of lupus based on genomic findings to enhance clinical
diagnosis and therapeutics.
Monogenic lupus
Rare genetic diseases provide valuable insights into more
common disorders. Focused analyses in families with multiple
lupus-like clinical phenotypes have led to the identification of
several monogenic causes of lupus that were subsequently
verified by association studies. One of the prototype mono-
genic pediatric lupus syndromes is Aicardi-Goutieres syn-
drome (AGS) characterized by encephalopathy, cerebral atro-
phy, basal ganglia calcifications, seizures, thrombocytopenia,
hypocomplementemia, and presence of multiple autoanti-
bodies. Due to the clinical similarity, several AGS patients
have been formally diagnosed with SLE. AGS involves reces-
sive and dominant mutations in RNAses (RNASEH2A,
RNASEH2B, RNASEH2C), a DNAse (TREX1), double-
stranded RNA (dsRNA) editing (ADAR), dsRNA recognition
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and binding (IFIH1), and activation of the innate immune
system (SAMHD1, IFIH1) (Crow et al. 2015).
TREX1 and IFIH1 have been shown to be associated with
SLE as well (Table 1). TREX1 is a major intracellular DNAse
with 3′ exonuclease activity leading to single-stranded DNA
degradation during caspase-independent apoptosis, minimiz-
ing autoimmune reactivity to self-DNA. InAGS, homozygous
mutations in TREX1 associated with loss of protein activity
are frequently found. In early-onset cerebral SLE, exome se-
quencing identified a pathogenic variant in TREX1 (Ellyard
et al. 2014) and a heterozygous mutation was shown to cause
familial chilblain lupus (Günther et al. 2009). A sequencing-
based association study of TREX1 exons in four European
SLE cohorts identified 12 heterozygous missense and frame-
shift changes in over 400 SLE patients (P = 1.7 × 10−7) (Lee-
Kirsch et al. 2007). In essence, these studies have not only
identified TREX1 as a major SLE gene but also unraveled part
of the lupus pathobiology where autoimmunity results from
aberrant processing of DNA during apoptosis.
Similarly, other DNAses have also been shown to be in-
volved in lupus viz. DNAse1L3, DNASE1, and POLB.
DNAse1L3 was identified to cause familial SLE in Middle
Eastern families with multiple affected children (Al-Mayouf
et al. 2011). These patients had positive ANA, dsDNA, and
ANCA antibodies; low C3 and C4; and high frequency of
nephritis. Linkage analysis located the locus to 3p14.3,
where an earlier genome-wide association study (GWAS)
peak was also noted (though attributed to a nearby gene,
PXK, 140 kb fromDNAse1L3; Table 1). DNAse1L3 sequenc-
ing found mutations which decreased protein activity or elim-
inated gene expression. Interestingly, it had been previously
shown that DNAse1L3 deficiency increases the susceptibility
of mice to polygenic SLE (Wilber et al. 2003). Moreover,
hypocomplementemic urticarial vasculitis syndrome
(HUVS) which shares similarity with SLE was found to result
from DNAse1L3 mutations in two Turkish families (Ozçakar
et al. 2013). Majority of these patients had positive ANA
and dsDNA antibodies; low C3 and C4, class II, III, and
glomerulonephritis (GN); and recurrent urticarial rash with
leukocytoclastic vasculitis, fever, anemia, lymphadenopathy,
and arthritis. ANCA was positive in two of five patients.
Due to clinical and immunologic similarity to SLE, HUVS
Table 1 Published SLE-associated genes
Innate Immunity
APOPTOSIS CYTOKINES INTERFERON TRANSCRIPTION
AFF1 22291604 IL10 19838195 IFIH1 22046141 HAND1 23740238 MYO18B 23740238
ATG5 21622776 IL21 21425124 IRF3 25130328 HIPK1 23740238 RASGRP3 23249952
ATG7 21622776 IL8 21179067 IRF5 24697319 IKBKE 21179067 SOS1 23740238
PDCD1 19220647 SPP1 15692970 IRF7 21360504 IRAK1 19329491 STAT4 24697319
REL 21905002 IL12A 26502338 IRF8 22046141 JAZF1 23740937 TRAF6 22231568
TREX1 17660818 SOCS1 26502338 PRDM1 19838195 MECP2 22904263 TNIP1 23249952
RAD51B 26502338 TYK2 22046141 MIR146a 21738483 TCF7 26502338
Adapve 
Immunity
B-CELL SIGNALING T-CELL SIGNALING ANTIGEN PRESENTATION OTHERS
BANK1 21408207 CD44 21194677 ERBB3 20962850
BLK 21480188 CTLA4 20962850 ICA1 20962850
CD40 21914625 PTPN22 21078766
CSK 23042117 TNFAIP3 21905002 CELL SIGNALING MEMBRANE PROTEIN UBIQUITINATION
LYN 19369946 TNFSF4 21905002 SPRED2 26502338 C3orf21 [XXYLT1] 23740238 SMURF1 23740238
PRKCB 21134959 TRAF1 21905002 NADSYN1 26502338 CADPS 23740238 UBE2L3 20962850
IKZF1 23249952 ELF1 21044949 SH2B3 26502338 SCUBE1 22039224 SKP1 26502338
IKZF2 26502338 ETS1 23249952 CIITA 26502338 DHCR7 26502338
IKZF3 22464253 SLC5A11 24925725 PLD2 26502338
Immune 
Complexes
PHAGOCYTOSIS COMPLEMENT CELL ADHESION UNKNOWN
CRP 24574329 CFB 21792837 TBL1XR1 23740238 CXORF21 26502338 TMEM39A 22464253
FCGR2A 15895258 CR2 25180293 PECAM-1 25201689 FAM78B 23740238 TNPO3 25205108
FCGR2B 16227149 CR5 25167769 ARHGAP26 23740238 KIAA0319L 23740937 TRAJ50 23740238
FCGR3A 17596285 CSMD1 23740238 DIAPH3 23740238 KIAA1542 21792837 UHRF1BP1 19838195
FCGR3B 22551723 MBL2 21792837 PDGFRA 24925725 LRRC18 23249952 WDFY4 20169177
ITGAM 18204098 HAS2 24925725 PEX5L 23740238 XKR6 20962850
ITGAX 18204098 PXK 18204446 ZBTB20 23740238
NCF2 22046141 SLC15A4 23249952 ZPBP2 22464253
Summary of genes in which variants are associated with SLE in GWAS and candidate association studies. The genes are grouped according to their
pathways. Numbers in parentheses indicate study PubMed IDs for easy reference
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is considered by some as an SLE-associated syndrome
(Aydogan et al. 2006). Additionally, HUVS is present in
∼8% of lupus patients, and SLE is observed in >50% of
HUVS patients during follow-up (Aydogan et al. 2006).
A small sequencing study found in 2 of 20 SLE patients, a
heterozygous non-sense mutation (A→ G transversion at po-
sition 172 in exon 2) decreased the activity of DNASE1, the
most abundant extracellular DNAse (Yasutomo et al. 2001).
Both these patients had positive ANA, dsDNA, SSA, and
RNP antibodies; fever; and generalized erythematous rash
and nephritis. Finemapping of a SLE GWAS signal on
8p11.21 identified POLB encoding DNA polymerase beta
(Pol β), which repairs single-strand DNA breaks (Sheng
et al 2011). It was shown that mutant POLB (Y265C) repairs
DNA significantly more slowly than do wild-type (WT) Pol
β, and mutant POLB mice develop dermatitis, GN, cervical
lymphadenopathy, and high titers of ANA, i.e., pathology
resembling SLE (Senejani et al. 2014).
All IFIH1mutations in AGS are dominant gain of function,
though majority of AGS is autosomal recessive. IFIH1 codes
for melanoma differentiation-associated gene 5 (MDA5), a
cytoplasmic receptor that binds to viral long dsRNA structures
and induces IFN-β production (Hall and Rosen 2010). IFIH1
was shown to be strongly associated with SLE in large asso-
ciation studies of European patients (Cunninghame Graham
et al. 2011; Gateva et al. 2009). Interestingly, MDA5 (encoded
by IFIH1) is associated with a dermatomyositis syndrome that
carries its name. MDA5 syndrome has been classified as an
amyopathic (absence of muscle involvement) dermatomyosi-
tis characterized by a specific 140-kD antibody in serum
(Betteridge et al. 2011), palmar papules, periungual erosions,
alopecia, arthritis, and severe interstitial lung disease (ILD)
with extremely poor prognosis (Fiorentino et al. 2011).
About 50% of MDA5 patients die of ILD within 6 months
of diagnosis (Nakashima et al. 2010). Though clinically dis-
tinct phenotypes are known to be encoded by different muta-
tions in a single gene (Deng et al. 2010; Fecto et al. 2011), it is
also possible that MDA5 is a monogenic lupus syndrome with
a specific antibody rather than dermatomyositis since being
clinically amyopathic is an essential feature of MDA5 or per-
haps the MDA5 antibody is also present in SLE cohorts given
the strong IFIH1 association. Inmice withMDA5 overexpres-
sion, there was increased interferon gene signature (IGS), re-
sistance to lethal viral infection and when combined with a
lupus susceptible background, production of autoantibodies
and GN was accelerated (Crampton et al. 2012). However,
in mice with a gain-of-function mutation in MDA5, a lupus
syndrome developed spontaneously and type I interferon sig-
naling was found to be crucial (Funabiki et al. 2014).
Another characteristic of AGS is elevated interferon-α
(IFN-α) levels in serum and CSF as well as IGS upregulation.
This is true for all AGSmutant genes including IFIH1. Recently,
the gene ACP5 encoding tartrate-resistant acid phosphatase
(TRAP) was discovered for Spondyloenchondrodysplasia
(SPENCD; MIM271550), a skeletal dysplasia syndrome
with intracranial calcifications, spasticity, and immuno-
logic abnormalities (Briggs et al. 2011). Of the ten study
patients with SPENCD, four also met the ACR criteria for
SLE, presenting with arthralgia/arthritis, seizures, rash,
cytopenias, LN (class IV and V), hypocomplementemia,
and positive ANA and dsDNA antibodies (Briggs et al.
2011). In SPENCD patients, serum IFN-α and IGS in
macrophages and dendritic cells were elevated, due to loss
of function mutations in ACP5.
We recently reported the association of apolipoprotein
L1 (APOL1) risk alleles with SLE collapsing glomerulop-
athy (CG) in the largest series to date of renal biopsies
from African-American patients with LN (Larsen et al.
2013). CG has uniformly poor prognosis with rapid pro-
gression to renal failure and no response to immunosup-
pression. We also showed that APOL1 variants are asso-
ciated with specif ic pathologic features such as
microcystic tubular dilatation (Larsen et al. 2015).
APOL1 risk alleles were previously shown to be associat-
ed with HIV nephropathy (HIVAN). Interestingly, HIV
and SLE, two pathogenically divergent processes, result
in very similar glomerular pathology, i.e., CG and even
proliferative GN (D’Agati and Appel 1997). Moreover
tubuloreticular inclusions on electron microscopy in the
glomerular endothelial cytoplasm are unique to HIV and
SLE (D’Agati and Appel 1997). Normal cells develop
these inclusions after exposure to elevated levels of
IFN-α (Rich 1995), and CG development has been report-
ed with pharmacologic interferon treatment (Rich 1995).
This morphologic overlap is likely a clue to the pathogen-
esis of CG and the type of inflammatory milieu that in-
cites disease, specifically elevated IFN levels. It also
strengthens the relationship of type I interferon signaling
with SLE.
Protein kinase C δ (PKCδ) encoded by the gene PRKCD, a
ser ine / th reonine kinase implica ted in apoptos is
(Mecklenbräuker et al. 2002), was shown to be linked to
SLE in a family of three affected siblings (Belot et al. 2013).
These patients had positive ANA and dsDNA antibodies,
hypocomplementemia, rash, LN, CNS vasculitis, lymphade-
nopathy, and hepatosplenomegaly. The mutant PKCδ de-
creased apoptosis in transitional and primary B-cells (Belot
et al. 2013). Similarly, mice deficient in PKCδ demonstrate
a defect in the negative selection of self-reactive B-cells, an
expansion of peripheral B-cells and develop features consis-
tent with SLE (Mecklenbräuker et al. 2002). Correspondingly,
an intronic variant (rs16972959) in PRKCB, a member of the
PKC-gene family and encoding PKCβ, was found to be asso-
ciated with SLE in a Han Chinese population (Sheng et al.
2011). In lupus-susceptible mice, PKCβ deficiency abolished
nephritis and autoantibody formation by inducing an anergic
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B-cell phenotype and treatment with the PKCβ-specific inhib-
itor enzastaurin prevented the development of lupus (Oleksyn
et al. 2013).
Hypocomplementemia is another theme that runs through
lupus. Detailed discussion on complement system involve-
ment in lupus pathogenesis has been presented elsewhere
(Macedo and Isaac 2016); however, briefly early complement
component deficiency leads to autoimmunity. SLE develops
in over 90% of C1q-deficient individuals though complete
deficiency of C1q is rare (Botto et al. 1998). Similarly, SLE
development is strongly associated with C4 deficiency (75%)
and to a lesser degree with homozygous C2 deficiency (10–
30%) though C2 deficiency is the most common in European
populations (0.5–1/104) (Botto et al. 2009). Complement de-
ficiencies were the first monogenic causes of lupus discovered
(Nishino et al. 1981; Hannema et al. 1984) and also became
one of the first diagnostic (Koffler et al. 1974; Schroeter et al.
1976) and subsequently predictive markers for SLE activity
(Swaak et al. 1986). Presence of multiple autoantibodies, rash,
arthritis, and LN are common features of SLE associated with
complement deficiencies. The significance of the complement
system is in clearance of apoptotic debris which is hampered
by its deficiencies.
Polygenic lupus
The perpetual cycle of immunologic abnormalities that de-
fines lupus was elucidated in 1963 and is based on aberrant
apoptosis followed by immune complex formation and depo-
sition (Sbarra et al. 1963). The recent addition of the IGS to
this cycle may provide another marker of SLE activity and
pathogenically be indicative of the central role of
plasmacytoid dendritic cells (pDCs) which are the major pro-
ducers of IFN-α. The intracellular signaling of apoptotic ma-
terial in pDCs is mediated by specialized receptor systems
such as MDA5 and Toll-like receptors (TLRs; Fig. 1). There
are ten TLR-members in humans; e.g., TLR3 is a receptor for
dsRNA; lipopolysaccharide (LPS) of gram-negative bacteria
is recognized by TLR4; and TLR7 is activated by ssRNAs and
TLR9 by unmethylated ssDNA (Akira et al. 2001; Panter et al.
2009). TLR signaling pathways are highly complex and me-
diate a variety of essential injury-and-repair processes includ-
ing phosphorylation; ubiquitination; and induction of inflam-
matory cytokines, apoptosis, and autophagy (Allam and
Anders 2008). Gene expression of TLR 2, 7, and 9 in periph-
eral blood mononuclear cells from SLE patients has been
found to be higher than healthy controls (Komatsuda et al.
2008). Aberrant signaling of TLRs is known to trigger auto-
immunity (Allam and Anders 2008) and the nucleic acid bind-
ing TLRs in particular have been implicated in SLE (Savarese
et al. 2008).
The BXSB male mice develop an accelerated, lupus-like
phenotype with severe nephritis (Blossom et al. 1997) due to
an X-to-Y chromosomal translocation of a gene cluster known
as Yautoimmune accelerator (Yaa) (Subramanian et al. 2006).
Subsequently, TLR7was identified as the causative gene in the






























































Fig. 1 SLE pathobiology based on genomic findings. SLE initiation:
aberrant apoptosis triggered by dysfunctional DNAses/RNAses activate the
endosomal TLR, MDA5, and related pathways in pDCs. Inherent B-cell
dysfunction and HLA-associated thymic T-cell negative selection may result
in autoantibody formation. SLE potentiation: increased IFN-α, dysfunctional
antigen presentation by pDCs, and inherent malfunctioning of T- and B-cells
leading to a proinflammatory milieu causes persistent tissue inflammation.
Consequent organ damage is exacerbated by defective IC clearance
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association (CGA) study reported that a functional polymor-
phism in 3′ UTR of TLR7 was associated with SLE in Asian
populations, with a stronger effect in male than female sub-
jects (Shen et al. 2010).
Genes associated with SLE located on the X-chromosome
may in part explain the extreme female preponderance of the
disease. This concept of the X-chromosome gene dose effect
in SLE is supported by the heightened prevalence of SLE in
Klinefelter’s syndrome (47,XXY), shown to be 2.2%, i.e., 13-
fold higher than in normal men and similar to that of normal
women (Scofield et al. 2008; Dillon et al. 2012). SLE-
associated genes located on the X-chromosome include
CXorf21, MECP2, and IRAK1 as well as TLR7 and TLR8
(Table 1). Variants in MECP2 may disinhibit its target genes
such as IRAK1 and lead to heightened IFN signaling.MECP2
is also involved in methylation with consequent aberrations in
gene expression in SLE. Though the function of CXorf21 is
unknown, it escapes X-inactivation and the large GWAS that
recently identified it also had a significantly higher prevalence
of Klinefelter’s in its male cases with SLE (Bentham et al.
2015). Skewed X-inactivation in certain tissues may predis-
pose to SLE development if the preferred parental X-
chromosome harbors these or other SLE-associated genes
(Weckerle and Niewold 2011).
TLR signaling leads to NFκB activation and IFN produc-
tion which in turn stimulates the JAK/STAT pathway leading
to release of proinflammatory cytokines. There are several
SLE-associated genes involved in these pathways including
IRAK1, TRAF6, IRF5, IRF7, STAT4, TNFAIP3, and TYK2
(Table 1 and Fig. 1). MicroRNAs (miRNAs) regulate TLR
and IFN signaling (Jacob et al. 2009a). They are non-coding
RNAs (19–25 nucleotides long), ubiquitously expressed
across evolutionary strata and regulate gene expression by
inhibiting mRNA translation and targeting specific mRNAs
for degradation. It has been shown that miR-146a inhibits
IRAK1, TRAF6, and IRF5 (Jacob et al. 2009a). It is upregu-
lated by TLR ligands and IFN, thus functioning as an induc-
ible repressor of the innate immune system (Wang et al.
2008a). Variants in miR-146a are associated with SLE and
prevent the normal downstream binding of the transcription
factor ETS1, which is also associated with SLE, leading to
disinhibition of the IFN pathway (Fig. 1) (Jacob et al.
2009a; Wang et al. 2008a).
The potential triggering of SLE through TLRs, MDA5,
JAK/STAT, and NFkB pathways in pDCs by viruses (e.g.,
RNA viruses such as picornaviruses), bacteria (LPS), and
products of aberrant apoptosis (dsDNA, ssDNA, and
dsRNA) has been discussed thus far. During pregnancy, fetal
cell transfer across placental interface into maternal circula-
tion, called microchimerism, could also act as a triggering
antigen for SLE flares (Fig. 1) (Arck and Hecher 2013).
Y-chromosome DNA can be detected by PCR in maternal
blood and tissues and is indicative of microchimerism.
Chimeric male cells in postmortem female organs were iden-
tified at significantly higher frequency in SLE patients than in
controls (Kremer Hovinga et al. 2007). Similarly, a vaccine
component may serve as an autoantigen as well. This rare
phenomenon is called autoimmune/inflammatory syndrome
induced by adjuvants (ASIA). Changes in ANA titers and
subsets have been reported in a small number (∼5%) of SLE
patients after vaccination, and there have been a few cases of
SLE onset or exacerbation following vaccination (Perdan-
Pirkmajer et al. 2012; Soldevilla et al. 2012). Rarity of this
phenomenon points to the robustness of the immune system at
dealing with foreign antigens and their low likelihood of being
causative for SLE in general.
Islet cell autoantigen 1 (ICA1) which is associated with
SLE (Table 1) was previously known to function as an
autoantigen in type I diabetes mellitus (Pietropaolo et al.
1993). Recently, it was shown that polymorphisms in ICA1
promoter may alter binding of the transcription factor AIRE,
resulting in downregulation of ICA1 expression in medullary
thymic epithelial cells leading to loss of immunologic toler-
ance to this self-antigen and triggering autoimmunity (Bonner
et al. 2012). Interestingly, mutations in AIRE lead to autoim-
mune polyendocrinopathy candidiasis ectodermal dystrophy
(APECED) in which multiple autoantibodies form against
several endocrine organs as well as against IFN, IL17, and
IL22 (Kluger et al. 2012). APECED does not clinically resem-
ble SLE, pointing to perhaps the significance of IFNs to SLE
pathogenesis. Anti-IL17 response is the likely cause of candi-
diasis seen in APECED.
Antigen presentation by pDCs is determined by HLA-
coded proteins (i.e., MHC) and subsequently leads to the gen-
eration of autoantibodies and immune complexes amplifying
both innate and adaptive immune responses. The HLA region
is subdivided into class I and class II regions, which contain
genes encoding glycoproteins that process and present pep-
tides for T-cell recognition and the class III region harboring
complement components (C2, C4A, C4B, and CFB), TNF,
and other immune genes. GWAS in both European and
Asian populations have shown that the strongest contribution
to risk for SLE resides in the HLA region and consists of
multiple genetic effects (Graham et al. 2009). However, due
to the long-range linkage disequilibrium (LD) of ∼1 Mb with-
in the HLA region, the exact susceptibility gene is hard to
identify. HLADRB1*1501 (DR2) andDR3 B1*0301 are class
II alleles consistently shown to be associated with SLE
(International MHC and Autoimmunity Genetics Network
et al. 2009). More recently, a large GWAS found that the best
model for association was a combination of HLA alleles
including B*08:01 and B*18:01 in class I, DQB1*02:01,
DRB3*02:00, and DQA*01:02 in class II and a class III
SNP (rs74290525) located in SLC44A4 (Bentham et al.
2015). Previously, the association signal in class III had
been fine mapped to the sixth intron of the SKIVL2 gene as
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well as to a SNP located between TNXB and CREBL1 and the
HLA DRB1*0301 (International MHC and Autoimmunity
Genetics Network et al. 2009).
TNF-ligand superfamily member 4 (TNFSF4) is expressed
on pDCs and interacts with its receptor, OX40L, on activated
T-cells. OX40L-mediated signaling inhibits the generation
and function of IL-10-producing CD4+ T-regulatory-cells
(Ito et al. 2006) but induces B-cell activation and differentia-
tion, as well as IL-17 production (Fig. 1) (Stüber et al. 1995).
Simultaneously, IFN-α is known to induce a proinflammato-
ry gain of function of IL-10, an important pleiotropic cyto-
kine involved in B-cell regulation (Sharif et al. 2004).
Binding of miR-21 to the 3′ UTR of RASGRP1 (Table 1)
activates the Erk–MAP kinase cascade leading to the inhibi-
tion of downstream target gene DNMT1, a methyltransferase
that is a major epigenetic regulator. Upregulation of miR-21
leads to DNA hypomethylation of CD4+ T-cells in SLE
(Jacob et al. 2009a). PTPN22 encodes a tyrosine-
phosphatase that inhibits T-cell activation. The non-
synonymous SNP rs2476601 associated with SLE is a gain-
of-function variant that reduces the threshold for T-cell-
receptor signaling and promotes autoimmunity (Kyogoku
et al. 2004). Blocking T-cell activation by CTLA4-Ig
prevented LN and delayed mortality in NZB/W F1 mice
(Finck et al. 1994). Kidneys of nephritic NZM2328 mice
show increased expression of Th1 cytokines (IFN-γ, IL-12)
(Jacob et al. 2009b) whereas in MRL/lpr mice, laser micro-
dissection of renal infiltrates showed increased Th1 and IL-17
expression (Wang et al. 2008b). Th17 expression profile re-
sulted in TNF-receptor-deficient NZM2328 mice in an accel-
erated onset of LN and higher mortality (Jacob et al. 2009b).
IL-17 was also found to be increased in ∼25% of SLE pa-
tients (Garrett-Sinha et al. 2008). Thus, Th1 and Th17 T-cells
play a significant role in SLE and interact with pDCs and B-
cells to coordinate the lupus immunologic cascade.
Several B-cell-related genes are associated with SLE
(Table 1).BLK encodes tyrosine-protein kinase Blk, a member
of the src kinases, which mediates the proliferation, differen-
tiation, and tolerance of B-cells. B-cell scaffold protein with
ankyrin repeats (BANK1) regulates direct coupling between
the src-tyrosine kinases and the calcium channel IP(3)R facil-
itating intracellular calcium release and altering B-cell activa-
tion threshold (Yokoyama et al. 2002). It has been shown in
mouse models that BANK1 regulates TLR7 signaling in B-
cells and that B-cell innate immune response via TLR7 is
critical for the development of autoimmunity (Wu et al.
2016; Walsh et al. 2012). Tyrosine-kinase lyn (LYN) mediates
B-cell activation by phosphorylating the activation motif of
the B-cell-receptor-associated Ig α/β signaling molecules and
mediates B-cell inhibition by phosphorylating inhibitory re-
ceptors such as CD22 (Hibbs et al. 2002). Lyn-overexpressing
mice developed autoantibodies and lethal LN (Hibbs et al.
2002). A transgenic mouse (MRL/lpr mice) expressing a
unique B-cell receptor leading to lack of circulating Ig has
been shown to develop LN (Chan et al. 1999). Therefore,
aberrant B-cell functioning plays a much more significant role
in SLE than perhaps antibody formation.
B-cell low-affinity IgG Fc-receptors (FcGRs) encoded by
FCGR2A, FCGR2B, FCGR3A, and FCGR3B are involved in
immune complex (IC) processing and clearance by antibody-
dependent responses (Table 1). Other SLE susceptibility genes
with important roles in IC processing are ITGAM, ITGAX, and
complement genes. ITGAM codes for an integrin, important in
the adherence of neutrophils and monocytes to stimulated en-
dothelium, and also in the phagocytosis of complement-
coated particles. A large GWAS comparing LN with SLE
patients in an attempt to discover LN susceptibility genes
found PDGFRA (involved in matrix synthesis, chemotaxis,
and cytokine production) and Hyaluronan synthetase 2
(HAS2; also involved in extracellular matrix production) to
be strongly associated (Chung et al. 2014).
There is substantial evidence that disease pathways interact
to create the lupus milieu. On a large SLE dataset of European
patients, gene interactions were detected between the HLA
region and CTLA4, IRF5, and ITGAM and between PDCD1
and IL-21 (Hughes et al. 2012). Another study showed
epistasis of BLK, TNFSF4, TRAF1, TNFAIP3, and REL
gene s i n SLE (Zhou e t a l . 2 012 ) . Mo r eove r ,
coimmunoprecipitation and colocalization experiments have
shown physical interaction between BLK and BANK1
(Castillejo-López et al. 2012). Similarly, epistasis has also
been demonstrated in mouse models of lupus (Morel et al.
2000).
It was previously thought that specific pathogenic autoan-
tibodies lead to target organ damage in SLE; however, passive
transfer of anti-dsDNA antibodies did not lead to LN
(Vlahakos et al. 1992) and immunoglobulins (Ig) eluted from
autopsy kidneys showed low cross-reactivity (0.3 to 41.3%
only) (Mannik et al. 2003). Moreover, about 15–26% of the
antibodies in SLE are polyreactive between a diverse antigen
panel that includes ssDNA, dsDNA, LPS, and insulin,
pointing to an aberrant B-cell response (Mietzner et al.
2008). In the absence of ANA, dsDNA in serum, or IgG eluted
from kidney homogenates, NZM2328.Lc4 mice developed
glomerular deposits and fatal LN (Mortensen and Rekvig
2009). Therefore, development of LN is not associated with
pathogenic autoantibodies of singular specificities and major-
ity of the antigens recognized by glomerular IgG deposits are
unknown.
Nevertheless, of all the nucleosomal antibodies in SLE,
dsDNA antibodies are potentially the most specific and path-
ogenic. Electron dense deposits (EDS) were seen in protein-
uric, lupus-susceptible NZB/W F1 mice (Mortensen and
Rekvig 2009). These EDSwere oligonucleosomes, containing
chromatin fragments and nucleosomal DNA deposited on the
glomerular basement membrane that were recognized by
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anti-dsDNA monoclonal antibodies. These oligonucleosomes
were the result of ineffective fragmentation and clearance of
apoptotic material in the renal glomerulus (Mortensen and
Rekvig 2009). It was also shown that anti-dsDNA antibodies
did not cross react with glomerular proteins and were specific
for the oligonucleosomes (Mortensen and Rekvig 2009).
Recently, PLA2R1 variants were shown to be associated
with SLE in a Chinese population (Li et al. 2016). PLA2R1
encodes the podocyte phospholipase A2 receptor (PLA2R)
against which autoantibodies are found to be directed in mem-
branous GN (Qin et al. 2011). We showed that in a large
biopsy-proven European cohort, a missense variant
( r s 35771982 ) i n PLA2R1 s t r ong l y a s s o c i a t e d
(P = 1.4 × 10−14) with PLA2R antibody-positive membranous
GN (Saeed et al. 2014). It is likely to be the functional variant
increasing PLA2R antigenicity index and interacting with
HLA-DQA1 (Saeed et al. 2014). We also showed that
PLA2R antibody-negative membranous GN was not associ-
ated. Moreover, APOL1 variants were found to be associated
with PLA2R-positive membranous GN (Larsen et al. 2014).
Taken together, these findings link PLA2R antibody-positive
membranous GN to SLE in a similar manner to MDA5 syn-
drome and AGS.
Therapeutics
SLE treatment has so far largely been guided by clinical ex-
perience.With the recent advent of targeted biologic therapies,
this paradigm has started to change. It only makes logical
sense that the therapeutics be guided by disease pathogenesis,
and some detailed studies evaluating the basic immunologic
effects of traditional immunosuppressants have recently been
published. In this section, we attempt to connect drug mech-
anisms with lupus pathobiology in the hope that this may
provide insight into future treatment options.
In severe lupus flares, pulse therapy with methylpredniso-
lone is instituted for 3–5 days which usually has a profound
clinical effect on disease activity, albeit temporary. It was
shown that methylprednisolone inhibited IGS and decreased
IFN-α levels and pDC numbers in mice, whereas predniso-
lone did not. Interestingly, the effect of methylprednisolone
lasted for about a week (Guiducci et al. 2010).
Hydroxychloroquine (HCQ) is a mandatory part of the
SLE treatment regimen. HCQ affects the endosomal TLR ac-
tivation by direct interaction with nucleic acid TLR ligands
(Kuznik et al. 2011). HCQ formed complexes with nucleic
acids in the endosomes leading to conformational changes in
the nucleic acids, thereby preventing TLR activation (Kuznik
et al. 2011). Similarly, TLR7 and TLR9 immunoregulatory
sequences (IRS) injected in MRL/lpr mice improved the ac-
tivity and chronicity indices for LN (Pawar et al. 2007). A
bifunctional TLR 7/9 IRS blocked IFN-α production and
PDC stimulation (Guiducci et al. 2010). Moreover, TLR7/9
signaling prevented glucocorticoid-induced apoptosis of
PDCs and B-cells. Thus, continuous signaling of TLR 7/9
was responsible for the reduced efficacy of glucocorticoids
at inhibiting the IFN pathway in SLE patients and lupus-
prone mouse strains (Guiducci et al. 2010). Hence, inhibitors
of TLR7/9 could prove to be effective corticosteroid-sparing
drugs in SLE.
One of the mouse models used in this study was a TLR7-
overexpressing transgenic mouse that developed a lupus-like
syndrome (Subramanian et al. 2006). It is also known that
TLR7 contributes specifically to anti-Sm-RNP antibodies
(Christensen et al. 2006), and U1snRNP RNAwas identified
as an endogenous ligand for TLR7 (Savarese et al. 2006).
Aberrant ssDNA processing by mutant TREX1may also stim-
ulate TLR9 (Crow et al. 2006). Therefore, the endosomal TLR
pathway is a potential therapeutic target for SLE of immense
significance.
Cyclophosphamide (CYC) is an alkylating agent and is one
of the most potent immunosuppressive drugs. It has a long
history of use as induction therapy for organ-threatening
SLE. CYC exerts its cytotoxic effect on predominantly B-
lymphocytes by crosslinking DNA with alkyl groups, thus
inhibiting DNA replication. Plasmablasts and plasma cells
are not affected by cyclophosphamide (Miller and Cole
1967; Fassbinder et al. 2015); however, naïve B-cells are rap-
idly depleted (Fassbinder et al. 2015). Azathioprine (AZA)
used in maintenance therapy for SLE, is a prodrug for 6-mer-
captopurine, a purine analog impeding DNA synthesis via
several enzymes including inosine monophosphate dehydro-
genase (IMPDH). It has been shown to also substantially re-
duce transitional and naïve B-cells in peripheral blood of SLE
patients (Eickenberg et al. 2012).
Mycophenolate mofetil (MMF) is used as an induction and
maintenance regimen in SLE. MMF is a prodrug of mycophe-
nolic acid which reversibly inhibits IMPDH, preferentially the
type-II form of the enzyme that is upregulated in activated
lymphocytes, leading to cell cycle arrest (Lee et al. 1985).
Plasmablasts and plasma cells were significantly reduced in
peripheral blood of MMF-treated patients with subsequent
effect on antibody production (Fassbinder et al. 2015;
Eickenberg et al. 2012). In contrast to CYC, T-cell subsets
are unaffected by both MMF and AZA. CYC treatment was
shown to increase peripheral blood CD8+ T-cells and pDCs
(Fassbinder et al. 2015). Interestingly, SLE patients have low
numbers of circulating pDCs likely thought to be due to tissue
infiltration by these cells (Cederblad et al. 1998). It has been
suggested that the rapid onset of action of CYC may be attrib-
uted to the more efficient inhibition of tissue inflammation
leading to early reconstitution of circulating pDCs and
CD8+ T-cells (Fassbinder et al. 2015).
Methotrexate (MTX) is often used to treat the arthritis in
SLE; however, it has been shown to suppress overall SLE
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disease activity as well (Miyawaki et al. 2013; Sakthiswary
and Suresh 2014). In an open-label study, low-dose MTX
(7.5 mg) improved anti-dsDNA antibody, C3 and C4 levels,
SLE disease activity, and had a steroid-sparing effect
(Miyawaki et al. 2013). A meta-analysis also showed a sub-
stantial beneficial effect of MTX on SLE activity
(Sakthiswary and Suresh 2014).
Targeted biologic therapy has revolutionized the treatment
of SLE. Rituximab (RTX) is a chimeric monoclonal antibody
against CD20 and affects B-cell subsets except plasma cells
(Fernández-Nebro et al. 2012). Though RTX did not show
superiority to conventional treatment regimens in SLE and
LN in two randomized controlled trials (Rovin et al. 2012;
Merrill et al. 2010), it has shown substantial benefit in several
observational studies (Duxbury et al. 2013). It is postulated
that lupus heterogeneity and perhaps stringent response
criteria may have caused this discrepancy and further clinical
trials are needed. It is important to note that RTX is far less
toxic than CYC and therefore advantageous to use in SLE
flares as induction therapy (Moroni et al. 2014).
Belimumab, approved for treatment of SLE, is a human
monoclonal antibody targeting B-cell activating factor
(BAFF), a TNF-like cytokine involved in B-cell survival
and differentiation. BAFF overexpression led to B-cell expan-
sion and a lupus-like syndrome in mice, whereas BAFF inhi-
bition delayed lupus onset (Boneparth and Davidson 2012).
Two large phase III Belimumab clinical trials in SLE showed
that the therapeutic effect of belimumab lasted 1 year with
reduction in SLE flares and steroid use; however, the onset
was delayed and therefore not considered suitable for acute
SLE (Boneparth and Davidson 2012). Belimumab decreased
naïve, transitional B-cells and plasmablasts (Boneparth and
Davidson 2012).
In contrast to murine studies mentioned above, CTLA4
blockade by Abatacept in randomized controlled trials did
not improve outcomes of LN when used on a background of
MMF/steroids or CYC/AZA (Furie et al. 2014; ACCESS
Trial Group 2014). However, a small open-label study showed
modest benefit in SLE and one of the LN trials showed that
Abatacept improved anti-dsDNA antibody and C3 and C4
titres (Furie et al. 2014; Danion et al. 2016).
In a phase Ib randomized controlled trial of sifalimumab, a
human anti-IFNα monoclonal antibody that specifically neu-
tralizes most IFNα subtypes, SLE disease activity decreased
in patients with high IGS at baseline in the combined
sifalimumab group compared to placebo. Since this was a
safety and dose study, the multiple sifalimumab dose groups
made comparisons difficult and overall, there was no differ-
ence from placebo (Petri et al. 2013). A subsequent random-
ized, double-blind, placebo-controlled study of sifalimumab
was barely significant (P = 0.053; though the a priori cutoff for
this trial was unconventionallyP = 0.1), and there was no clear
dosage effect (Khamashta et al. 2016). Similarly, a phase II
trial of another anti-IFN-α monoclonal antibody,
rontalizumab, failed to meet its primary and secondary end-
points (Kalunian et al. 2016). However, recently, an IFN-α
receptor monoclonal antibody, anifrolumab, significantly re-
duced SLE disease activity across multiple clinical global and
organ-specific endpoints compared to placebo (Furie et al.
2015). SLE with high IRS responded better and it is hoped
that IRS may evolve into a treatment prediction tool. Phase III
trial of anifrolumab in SLE is underway and if the results hold,
anifrolumab could be approved for treatment of SLE as well.
The superior response of anifrolumab to anti-IFN-α protein
monoclonals also strengthens the concept of cellular inhibi-
tion in SLE through receptor inhibition, rather than ameliorat-
ing cytokine responses.
Summary
With now over a 100 known genes, lupus pathobiology has
been transformed. It is clear that multiple immunologic path-
ways are activated and interact to lead to the clinical syndrome
we recognize as SLE. From the vast genomic findings, few
key features have emerged, summarized in Fig. 1. In essence,
at the cellular level, pDC and B-cells appear to be the predom-
inant cell types involved in SLE. T-cells may play coordina-
tive (Th1) as well as partially cytotoxic (Th17) roles. Aberrant
B-cell functioning is involved in both autoantibody produc-
tion and ineffective IC clearance. The cycle of immunologic
abnormalities may be triggered by foreign or self-antigens;
however, the perpetuation of this cycle is of far greater signif-
icance and is due to a variety of genetic defects as detailed
here.
In the near future, genomics tools may enhance the diag-
nostic capabilities of physicians taking care of SLE patients,
just as nuclear antibodies and complement components do.
The IGS has already been used in recent clinical trials (Petri
et al. 2013; Kalunian et al. 2016). The challenge will be more
robust clinical classification of SLE. As more antibodies are
discovered, such asMDA5 and PLA2R, and genetic tests seep
into clinical practice, it is likely that SLE classification may
change further. Perhaps, SLE clinical definition may incorpo-
rate a mandatory presence of nuclear antibodies (ANA and its
subsets) and the nuclear-antibody negative SLE may be clas-
sified according to the specific antibodies or mutation find-
ings. In that case, PLA2R antibody-positive disease will be
defined as a syndrome in its own right outside lupus and
IFIH1 mutation-positive disease will be classified under the
MDA5 syndrome not associated with either dermatomyositis
or SLE. On the other hand, expert panels may take a more
inclusive approach by subclassifying SLE into more refined
phenotypes. Whatever the course SLE classification takes in
the future, genetic exploration of this complex disease has not
8 Immunogenetics (2017) 69:1–12
only enhanced its own pathobiology but opened doors to un-
derstanding autoimmune disease in general as well.
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